Assessment of Tumor Response and Resection Rates in Unresectable Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab

摘要: To investigate efficacy and safety of cetuximab combined with neo adjuvant chemotherapy regimen in patients unresectable colorectal liver. This was a prospective trial rate Ro liver metastases resection as primary end point. Between January 2010 December 2014, 46 from colon or rectum were enrolled. Patients received Cetuximab along neoadjuvant where 34 (74 %) 12 (2 6 FOLFOX FOLFIRI, respectively. They assessed for response after 2–3 cycles by CT scan. resectable disease offered surgery within 3–6 weeks the last treatment cycle. The point metastases, which evaluated all patients. Secondary points according to Response evaluation criteria solid tumors (RECIST) criteria, perioperative morbidity mortality. An objective observed 28 (60.9 Seven (15.2 reported radiologically have complete (CR); 21 (45.7 had radiological partial (PR). additional (26.1 demonstrated stable (SD) only six (13.0 progression (PD). Microscopically resections (R0 resection) performed %). most frequent toxicities skin rash diarrhoea. There no operative Chemotherapy yields high rates compared historical controls, leads significantly increased resectability. Complete previously can be minimal therapeutic strategy involves multimodal approach.